Quotidian Technical Highlights on Selected Medical Supplies Stocks -- Antares Pharma, DENTSPLY SIRONA, Integra LifeSciences, and Baxter Intl.

NEW YORK, Dec. 15, 2017 /PRNewswire/ --

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on ATRS, XRAY, IART, and BAX which is a click away at www.wallstequities.com/registration. Today's attention has been redirected to the Medical Instruments and Supplies industry, which primarily researches, develops, and produces nonelectronic medical, surgical, dental, and veterinary instruments and apparatus. This morning, WallStEquities.com observes the recent performance of Antares Pharma Inc. (NASDAQ: ATRS), DENTSPLY SIRONA Inc. (NASDAQ: XRAY), Integra LifeSciences Holdings Corp. (NASDAQ: IART), and Baxter International Inc. (NYSE: BAX). Wall St. Equities has a wide array of free research reports which include today's stock picks, register now to access them at: www.wallstequities.com/registration

Antares Pharma

On Thursday, shares in Ewing, New Jersey headquartered Antares Pharma Inc. recorded a trading volume of 1.40 million shares. The stock ended at $1.93, declining 1.53% from the last trading session. The Company's shares have gained 10.29% in the last one month. The stock is trading below its 50-day moving average by 10.62%. Furthermore, shares of Antares Pharma, which focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide, have a Relative Strength Index (RSI) of 54.53. Follow the link below to your free research report on ATRS at: www.wallstequities.com/registration/?symbol=ATRS

DENTSPLY SIRONA

York, Pennsylvania headquartered DENTSPLY SIRONA Inc.'s stock finished yesterday's session 0.62% lower at $65.65 with a total trading volume of 937,196 shares. The Company's shares have gained 0.40% in the last one month, 10.63% over the previous three months, and 13.72% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 3.65% and 5.98%, respectively. Furthermore, shares of DENTSPLY SIRONA, which designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide, have an RSI of 53.47. 

On December 12^th, 2017, DENTSPLY SIRONA announced that its Board of Directors declared a quarterly cash dividend of $0.0875 per share of common stock, an indicated annual rate of $0.35 per share. The dividend is payable on January 12^th, 2018, to holders of record on December 29^th, 2017. 

On December 13^th, 2017, research firm JP Morgan upgraded the Company's stock rating from 'Neutral' to 'Overweight'. The free technical report on XRAY can be accessed at: www.wallstequities.com/registration/?symbol=XRAY

Integra LifeSciences Holdings

At the close of trading on Thursday, shares in Plainsboro, New Jersey headquartered Integra LifeSciences Holdings Corp. rose 0.26%, ending the day at $50.14. The stock recorded a trading volume of 1.01 million shares, which was above its three months average volume of 606,510 shares. The Company's shares have advanced 5.83% in the last one month and 16.89% since the start of this year. The stock is trading 2.90% and 3.15% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Integra LifeSciences, which develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery, have an RSI of 62.23. Sign up for free on Wall St. Equities and claim the latest report on IART at: www.wallstequities.com/registration/?symbol=IART

Baxter International

Deerfield, Illinois headquartered Baxter International Inc.'s shares ended the day 0.09% higher at $64.78. A total volume of 3.41 million shares was traded, which was above their three months average volume of 2.42 million shares. The stock has gained 0.50% in the last month, 1.28% over the previous three months, and 46.10% on an YTD basis. The Company's shares are trading 1.08% above their 50-day moving average and 8.54% above their 200-day moving average. Additionally, shares of Baxter, which provides a portfolio of renal and hospital products, have an RSI of 53.75. 

On December 11^th, 2017, Baxter announced that it will present at the 36^th Annual J.P. Morgan Healthcare Conference on January 08^th, 2018, in San Francisco, California. José E. Almeida, Chairman and CEO, is scheduled to present at 10:00 a.m. PST that day. The live webcast of the presentation, along with accompanying slides, can be accessed on the Company's website. See the free research coverage on BAX at: www.wallstequities.com/registration/?symbol=BAX

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Wall St. Equities